APA (7th ed.) Citation

MC, H., KM, R., SE, L., KW, L., CC, C., CI, C., . . . HP, C. (2022). An Observational Study of Trifluridine/Tipiracil-Containing Regimen Versus Regorafenib-Containing Regimen in Patients With Metastatic Colorectal Cancer. Frontiers in oncology, 12, 867546. https://doi.org/10.3389/fonc.2022.867546

Chicago Style (17th ed.) Citation

MC, Hsieh, Rau KM, Lin SE, Liu KW, Chiu CC, Chen CI, Song LC, and Chen HP. "An Observational Study of Trifluridine/Tipiracil-Containing Regimen Versus Regorafenib-Containing Regimen in Patients With Metastatic Colorectal Cancer." Frontiers in Oncology 12 (2022): 867546. https://doi.org/10.3389/fonc.2022.867546.

MLA (9th ed.) Citation

MC, Hsieh, et al. "An Observational Study of Trifluridine/Tipiracil-Containing Regimen Versus Regorafenib-Containing Regimen in Patients With Metastatic Colorectal Cancer." Frontiers in Oncology, vol. 12, 2022, p. 867546, https://doi.org/10.3389/fonc.2022.867546.